STING1 and cancer: Since approximately half of all malignancies are treated with RT, and RT mediates in situ cancer vaccination (i.e., priming of antitumor T cells) by inducing STING signaling, identifying routes to maximize STING-induced IFN responses to RT may yield tremendous clinical value.